AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00921245 — intervention group
Intervention type: DRUG
Intervention: Darifenacin (Emselex, BAY79-4998)
Description: Patients in daily clinical treatment receiving Emselex according to local drug information
Study NCT03818984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer Conception for Men with At Risk Partners
Description: CBT based safer conception counseling with longitudinal follow-up and booster sessions. The primary outcome will be HIV RNA suppression at 6 months. Secondary outcomes include early ART uptake, adherence, serostatus disclosure, couples HIV counseling and testing uptake, and limiting unprotected sex to peak fertility.
Study NCT02044497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral oxycodone
Study NCT01931670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01931670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Study NCT01840839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation
Study NCT01840839 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Study NCT01541345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone graft
Description: Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
Study NCT01541345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: InductOs
Description: CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
Study NCT01541345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmentation surgery
Description: CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
Study NCT03686644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wearing of night splint ankle foot orthoses (phase A)
Description: Children wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results.
Study NCT03686644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No wearing of night splint ankle foot orthoses (phase B)
Description: Children no wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results.
Study NCT00859261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental 3D Breast Ultrasound imaging
Description: Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.
Study NCT00859261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental Photoacoustic Imaging
Description: Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
Study NCT01736657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red blood cell exchange in sickle cell
Description: One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
Study NCT02597816 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Three dimensional ultrasound
Study NCT02326311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib
Description: Tyrosin kinase inhibitor
Study NCT02326311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: Tyrosin kinase inhibitor
Study NCT02326311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nilotinib
Description: Tyrosin kinase inhibitor
Study NCT02326311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Tyrosin kinase inhibitor
Study NCT02326311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib
Description: Tyrosin kinase inhibitor
Study NCT02326311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tyrosin kinase inhibitor
Study NCT02876640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT02876640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoid 9cUAB30
Description: Given PO
Study NCT02876640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo tumor resection surgery
Study NCT00946400 — intervention group
Intervention type: OTHER
Intervention: Scoring 4Ts and Chong scale
Description: Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
Study NCT00946400 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
Study NCT05715879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: covid infection
Description: patients with covid infection which was proved with positive test
Study NCT05715879 — intervention group
Intervention type: BIOLOGICAL
Intervention: admission to hispital
Description: patients with sever covid disease, who was admitted in hospital
Study NCT03989726 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF ablation
Description: AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation
Study NCT03989726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation
Description: AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation
Study NCT04062318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online active TMS
Description: One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold.
Study NCT04062318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online active TMS
Description: One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold.
Study NCT01285947 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thermage
Description: Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm
Study NCT01285947 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Needle Application
Description: 30-gauge needle insertion into skin
Study NCT01285947 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VBeam Laser
Description: Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20
Study NCT01285947 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ulthera
Description: Ultrasound Device at the following settings:~Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm
Study NCT04823416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Left hemicolectomy
Study NCT04823416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stoma
Description: Colostomy
Study NCT02151136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24% sucrose
Study NCT02151136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Study NCT02151136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
Study NCT02151136 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
Study NCT03555838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation, a form of neuromodulation that uses a low direct current delivered via sponge electrodes on the head.
Study NCT01522820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01522820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01522820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO or PEG
Study NCT04550507 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindful sensory awareness + mindful body awareness check-ins intervention
Description: During the intervention period for Group B: Mindful Sensory \& Body Awareness(the second 8 weeks), they will receive the same mindful sensory awareness intervention, and also learn the mindful body awareness check-ins to guide media use choices strategy (referred to here as the check-ins component). We will coach youth to pause briefly every 30 minutes during media use to discern if they detect physical, cognitive, or emotional signs of escalated state arousal, and to make an intentional and real-time choice about possible changes in media use content or duration to help decrease state arousal levels before bed.
Study NCT04554290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: temporal artery biopsy
Description: description of temporal artery biopsy features, and its correlation with diagnosis of giant cell arteritis or other differential diagnoses.
Study NCT00567463 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
Study NCT03608228 — intervention group
Intervention type: OTHER
Intervention: Measuring electrical signals from the brain
Description: If patients participate in this study, after the deep brain stimulator leads have been implanted, the researcher(s) will plan to measure electrical signals from the brain while patients perform hand movement tasks.
Study NCT04553536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine, Sulfentanil or/and Remifentanil
Description: The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
Study NCT04553536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine, Sulfentanil or/and Remifentanil
Description: The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
Study NCT02793778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CROWN
Description: A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
Study NCT02793778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CROWN Placebo
Description: Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
Study NCT02741193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Magstim Rapid2,
Description: Transcranial Magnetic Stimulation, which is a microprocessor-controlled machine which delivers both single and repetitive transcranial magnetic stimulation (TMS).~single and repetitive transcranial magnetic stimulation (TMS). TMS will be applied as single pulses to determine motor evoked potentials (MEPs), there will be no modulation of cortical excitability.
Study NCT01640535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast + Levocetirizine
Description: Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
Study NCT01640535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
Study NCT01640535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
Study NCT02129881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous regulatory T Cell Product
Description: Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
Study NCT00725231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
Study NCT00725231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
Study NCT03555838 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: an inactive or placebo version of transcranial direct current stimulation placed on the head via sponge electrodes.
Study NCT00725231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
Study NCT00641940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls in Transition (GT) program
Description: In the 11-session after-school GT program, girls learn cognitive and behavioral skills related to intrapersonal, interpersonal, and social/contextual risk factors for depression.
Study NCT01045265 — intervention group
Intervention type: OTHER
Intervention: Seminal plasma pharmacokinetics
Description: Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
Study NCT00641940 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control
Description: Participants in the waitlist control group will complete the GT program during the third year of the study.
Study NCT01689506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volulyte
Description: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
Study NCT01689506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Serum Albumin
Description: 5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
Study NCT03778229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: osimertinib (80 mg oral OD).
Study NCT03778229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: savolitinib
Description: savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)
Study NCT03778229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: savolitinib
Description: savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)
Study NCT03778229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to osimertinib (oral OD)
Study NCT06209957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local corticosteroid injection
Description: Local corticosteroid injection;1 ml of triamcinolone acetonide 40 milligram/1.0 mL
Study NCT06209957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich Plasma Local injection
Description: Platelet-rich Plasma (From 2-step centrifugation of patient blood) Local injection.
Study NCT02977091 — intervention group
Intervention type: OTHER
Intervention: change in fitness level
Description: fitness level assessed by the Euro-fit tests for school age children.including 1.body fat 2. single leg balance test 3.Plate Tapping -for speed of limb movement 4.Sit-and-Reach flexibility test 5. Standing Broad Jump - measures explosive leg power. 6.Handgrip Test - measures static arm strength 7.Sit-Ups in 30 seconds - measures trunk strength 8.Bent Arm Hang - muscular endurance/functional strength 9.20 m endurance shuttle-run - cardiorespiratory endurance Wingate anaerobic test which is a 30 seconds maximum pedaling against resistance on bike for evaluating the anaerobic fitness
Study NCT02605694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: 25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
Study NCT04352127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TetraGraph
Description: FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
Study NCT02053246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
Study NCT01948310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Comparison of Ranolazine 1000mg twice per day versus placebo twice per day
Study NCT04057963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional plus Functional Inspiratory Muscle Training Group
Description: functional inspiratory muscle training is an exercise program that practises gradual training of the diaphragm muscle.
Study NCT04057963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy Program
Description: conventional physiotherapy is a treatment program consisting of evidence based modalities as mobilization and specific exercises.
Study NCT02951923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Bovine colostrum vs. soy during rugby training
Study NCT02951923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy
Study NCT02903511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Monitoring of safety and tolerability
Study NCT03198923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer and natural killer T cell
Description: The eligible patients are infused with 10 doses of (2-2.5)x10\^9 NK and NKT cells in one course of treatment.
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Administered orally
Study NCT02903511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monitoring of safety and tolerability
Study NCT01644045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Teleconsultation for the EMS in acute respiratory emergencies
Study NCT01924715 — intervention group
Intervention type: BEHAVIORAL
Intervention: ISTDP
Description: An emotion focused brief psychotherapy format.
Study NCT01542372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication augmentation
Study NCT01542372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Study NCT02273115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin